作者: Kenneth SH Chok , Tan To Cheung , Regina CL Lo , Ferdinand SK Chu , Simon HY Tsang
DOI: 10.1002/LT.23892
关键词: Randomized controlled trial 、 Ablation 、 Ascites 、 Liver transplantation 、 High-intensity focused ultrasound 、 Liver disease 、 Surgery 、 Medicine 、 Liver function 、 Hepatocellular carcinoma 、 Urology
摘要: The objective of this study was to investigate the outcomes high-intensity focused ultrasound (HIFU) ablation as a bridging therapy for patients with hepatocellular carcinoma (HCC) who had been wait-listed deceased donor liver transplantation (DDLT). Adult unresectable and unablatable HCCs within University California San Francisco criteria DDLT were screened their suitability HIFU if they not suitable transarterial chemoembolization (TACE). Treatment receiving ablation, TACE, best medical treatment (BMT) compared. Fifty-one included in analysis. Before introduction only 39.2% received (TACE only, n = 20). With use, rate increased dramatically 80.4% (TACE + HIFU, n = 41). overall dropout 51% (n = 26). Patients BMT group significantly higher (P = 0.03) poorer function reflected by Model End-Stage Liver Disease scores Child-Pugh grading. Clinically relevant ascites found 5 2 group, but none TACE (P = 0.01 P = 0.03, respectively). groups comparable percentages tumor necrosis excised livers (P = 0.35), both than that P = 0.02, In conclusion, safe even HCC C disease. Its adoption percentage from 80.4%. A randomized controlled trial further validation its efficacy is warranted. Transpl 20:912–921, 2014. © 2014 AASLD.